

The Portfolio of Diabetes and Weight Management


































Paglino reduces CV and Renal adverse outcomes in patients with T2D.

Paglino reduces the combined risk of cardiovascular death or hospitalization for heart failure.

- The recommended dose of Paglino is 10 mg once daily in the morning.
- For additional glycemic control, dose may be increased to 25 mg.
- Faglino can be taken with or without food.
- ¶ Paglino can be prescribed in patients with eGFR \geq 30 ml/min/1.73 m².

References:

FDA label on empagliflozin tablets, revised 2021. Empagliflozin drug information, UpToDate.com, accessed 2022.







Exceed the Limits





Paglimet is recommended for T2D patients to reduce the risk of ASCVD, HF and CKD outcomes in addition to glycemic control.

- Individualize the starting dose of Paglimet based on the patient's current regimen for additional glycemic control.
- The maximum recommended total daily dose is 25 mg empagliflozin, and 2000 mg metformin.
- Take twice daily with meals, with gradual dose escalation to reduce the gastrointestinal side effects due to metformin.
- Paglimet can be prescribed in patients with eGFR ≥45 ml/min/1.73 m².

References:

FDA label on empagliflozin and metformin hydrochloride tablets, revised 2022. Empagliflozin and metformin drug information, UpToDate.com, accessed 2022.





Paglimet ER is recommended for T2D patients to reduce the risk of ASCVD, HF and CKD outcomes.

Paglimet ER improves patient compliance due to the extended-release formulation of metformin.

- Individualize the starting dose of Paglimet ER based on the patient's current regimen.
- The maximum recommended total daily dose is 25 mg empagliflozin, and 2000 mg metformin.
- Take once daily with a meal in the morning, with gradual dose escalation to reduce the gastrointestinal side effects due to metformin.
- Paglimet ER can be prescribed in patients with eGFR \geq 45 ml/min/1.73 m².

References:

FDA label on empagliflozin and metformin hydrochloride extended-release tablets, revised 2021. Empagliflozin and metformin drug information, UpToDate.com, accessed 2022.



Life is a BALANCE



Avamet ER





Avamet can control HbA1c without risk of hypoglycemia.

Individualize the starting dose of Avamet based on the patient's current regimen.

- Maximum recommended dose is 2.5 mg linagliptin/1000 mg metformin twice daily
- Take twice daily with meals, with gradual dose escalation to reduce the gastrointestinal side effects due to metformin.
- Avamet can be prescribed in patients with eGFR > 45 ml/min/1.73 m².

References:

FDA label on linagliptin and metformin hydrochloride tablets, revised 2020. Linagliptin and metformin: Drug information, UpToDate.com, 2022.





Avamet ER can control HbA1c without the risk of hypoglycemia.

Avamet ER improves patient compliance due to the extended-release formulation of metformin.

- Individualize the starting dose of Avamet ER based on the patient's current regimen.
- Maximum recommended daily dose is 5 mg linagliptin/2000 mg metformin.
- Take once daily with a meal, with gradual dose escalation to reduce the gastrointestinal side effects of metformin.
- �� Avamet ER can be prescribed in patients with eGFR ≥45 ml/min/1.73 m².

References:

FDA label on linagliptin and metformin hydrochloride extended-release tablets, revised 2021. Linagliptin and metformin drug information, UpToDate.com, 2022.











AVANO can reduce the risk of ASCVD, HF and CKD outcomes along with achieving HbA1c targets in patients with T2D.

- The recommended dose is 10 mg empagliflozin/ 5 mg linagliptin once daily, take in the morning, with or without food.
- Dose may be increased to 25 mg empagliflozin/5 mg linagliptin once daily.
- \P AVANO can be prescribed in patients with eGFR ≥30 ml/min/1.73 m².

References:

FDA label on empagliflozin and linagliptin tablets, revised 2020.
Empagliflozin and linagliptin drug information, UpToDate.com, 2022.



AVANOMETER

Empagliflozin / Linagliptin / Metformin

The Ultimate Balance







AVANOMET ER can provide CV and renal benefits with additional HbA1c reduction.

AVANOMET ER improves patient compliance due to ER formulation of metformin.



Individualize the starting dose based on the patient's current regimen.







References:

FDA label on empagliflozin, linagliptin, and metformin hydrochloride extended-release tablets, revised 2020.

Empagliflozin, linagliptin, and metformin drug information, UpToDate.com, 2022.








Melitide consists of liraglutide which reduces the risk of CV events, and promotes weight loss in patients with T2D.

Liraglutide is recommended as the first choice for injectable therapy in most T2D patients.



Adult Dosing: 0.6 mg once daily for 1 week, then increase to 1.2 mg once daily; if optimal glycemic response is not achieved after an additional week of treatment, may increase further to 1.8 mg once daily.

Pediatric Dosing: 0.6 mg once daily for at least 1 week; may increase by 0.6 mg/day increments at weekly intervals to achieve glycemic control (week 2: increase to 1.2 mg once daily; week 3: increase to 1.8 mg once daily).

References:

FDA label on liraglutide injection for subcutaneous use, revised 2019. Liraglutide drug information, UpToDate.com, 2022.





Maciza consists of liraglutide which is used for adults with excess weight (BMI \geq 27) who also have weight-related medical problems or obesity (BMI \geq 30), and children aged 12-17 years with a body weight above 60 kg and obesity to help them lose weight and keep the weight off.



Inject Maciza subcutaneously once-daily at any time of the day, independently of meals, in the abdomen, thigh or upper arm.



Adult Dosing: 0.6 mg once daily for 1 week; increase by 0.6 mg daily at weekly intervals to a target dose of 3 mg once daily. If the patient cannot tolerate an increased dose during dose escalation, consider delaying dose escalation for 1 additional week.



Pediatric Dosing: 0.6 mg once daily for 1 week; increase as tolerated by 0.6 mg/day increments at weekly intervals to a target dose of 3 mg once daily. If the 3 mg target daily dose is not tolerated, reduce dose to 2.4 mg daily; discontinue if the 2.4 mg dose is not tolerated.

References:

FDA label on liraglutide injection for subcutaneous use, revised 2022. Liraglutide drug information, UpToDate.com, 2022.









ارکیدلایف با هدف خدمت رسانی و پاسخگویی به سوالات بیماران مصرفکننده داروهای تحت فروش ارکیدفارمد در سال ۱۳۹۳ به عنوان واحد پیشنت ساپورت (حمایت از بیمار) پایهگذاری شده است.

خدمات اركيدلايف

- پاسخگویی ۲۴ ساعته
- راهنمایی جهت پوشش بیمهای و روند تهیه دارو
- معرفی نزدیکترین داروخانه برای دسترسی سریع بیمار به دارو
 - آموزش نحوه نگهداری و مصرف صحیح دارو
 - ارائه فیلم و متریال آموزشی
- راهنمایی جهت عوارض احتمالی دارو و راه های مقابله با آن
 - اطلاع رسانی های دارویی
 - برگزاری همایش بیماران و پرستاران

